Yarger Wealth Strategies LLC Has $103,000 Position in agilon health, inc. (NYSE:AGL)

Yarger Wealth Strategies LLC lessened its holdings in agilon health, inc. (NYSE:AGL) by 12.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 53,966 shares of the company’s stock after selling 7,655 shares during the period. Yarger Wealth Strategies LLC’s holdings in agilon health were worth $103,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. State Street Corp raised its holdings in shares of agilon health by 3.0% during the third quarter. State Street Corp now owns 7,449,706 shares of the company’s stock worth $29,277,000 after acquiring an additional 215,733 shares in the last quarter. Geode Capital Management LLC increased its position in agilon health by 1.2% in the 3rd quarter. Geode Capital Management LLC now owns 6,893,517 shares of the company’s stock worth $27,097,000 after purchasing an additional 84,889 shares during the last quarter. Citigroup Inc. increased its position in agilon health by 2,251.5% in the 3rd quarter. Citigroup Inc. now owns 2,028,246 shares of the company’s stock worth $7,971,000 after purchasing an additional 1,941,993 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of agilon health by 326.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,415,419 shares of the company’s stock worth $5,563,000 after purchasing an additional 1,083,492 shares in the last quarter. Finally, AQR Capital Management LLC lifted its holdings in shares of agilon health by 3,338.5% during the 2nd quarter. AQR Capital Management LLC now owns 1,356,438 shares of the company’s stock valued at $8,871,000 after buying an additional 1,316,990 shares during the last quarter.

Insiders Place Their Bets

In related news, Director Diana Mckenzie bought 12,500 shares of the company’s stock in a transaction dated Monday, November 25th. The stock was acquired at an average cost of $2.28 per share, with a total value of $28,500.00. Following the acquisition, the director now owns 51,319 shares in the company, valued at approximately $117,007.32. This represents a 32.20 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Karen Mcloughlin purchased 25,000 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The stock was bought at an average cost of $2.20 per share, for a total transaction of $55,000.00. Following the purchase, the director now owns 73,166 shares in the company, valued at $160,965.20. This represents a 51.90 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired a total of 90,000 shares of company stock worth $198,100 over the last quarter. Company insiders own 3.20% of the company’s stock.

Analysts Set New Price Targets

AGL has been the topic of a number of research reports. Citigroup upgraded agilon health from a “sell” rating to a “neutral” rating and increased their price objective for the stock from $1.75 to $2.25 in a report on Friday, January 10th. Sanford C. Bernstein raised their price target on shares of agilon health from $2.50 to $3.15 and gave the company a “market perform” rating in a report on Wednesday. JMP Securities lowered shares of agilon health from an “outperform” rating to a “market perform” rating in a research note on Monday, November 11th. Stifel Nicolaus lowered their target price on shares of agilon health from $7.00 to $2.00 and set a “hold” rating on the stock in a research report on Tuesday, November 12th. Finally, Needham & Company LLC started coverage on agilon health in a research report on Friday, January 10th. They issued a “hold” rating for the company. Two analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, agilon health presently has an average rating of “Hold” and an average target price of $4.03.

agilon health Price Performance

Shares of NYSE AGL opened at $2.97 on Friday. agilon health, inc. has a 12 month low of $1.50 and a 12 month high of $7.73. The company has a quick ratio of 1.29, a current ratio of 1.29 and a debt-to-equity ratio of 0.06. The business’s 50 day moving average is $2.07 and its two-hundred day moving average is $3.67.

agilon health (NYSE:AGL) last released its earnings results on Thursday, November 7th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.19). The company had revenue of $1.45 billion for the quarter, compared to analyst estimates of $1.47 billion. agilon health had a negative net margin of 6.88% and a negative return on equity of 47.84%. During the same quarter in the previous year, the company earned ($0.06) earnings per share. On average, analysts predict that agilon health, inc. will post -0.59 earnings per share for the current year.

About agilon health

agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc and changed its name to agilon health, inc.